Efficacy and safety analysis of monthly minodronic acid in Japanese osteoporotic patients switched from traditional bisphosphonates
Not Applicable
- Conditions
- Osteoporosis
- Registration Number
- JPRN-UMIN000009575
- Lead Sponsor
- Ken-Ai Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with 1. Esophageal stricture or achalasia 2. Incapability in remaining upright for 30 min 3.Hypersensitivity to minodronic acid and other bisphosphonates 4. Hypocalcemia 5. Pregnancy 6. Aphagia, Esophagitis, Gastritis, Duodenitis or Ulcers 7. Severe renal dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone mineral density Bone turnover marker
- Secondary Outcome Measures
Name Time Method ow back pain Abdominal symptoms Preference and adherence for BPs Osteoporotic fracture
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie minodronic acid's efficacy in osteoporosis versus traditional bisphosphonates?
How does monthly minodronic acid compare to weekly bisphosphonates in improving BMD and reducing fractures in Japanese osteoporosis patients?
Which biomarkers predict response to minodronic acid in Japanese osteoporotic patients with varying baseline BMD levels?
What long-term adverse events are associated with monthly minodronic acid in Japanese osteoporosis patients, and how are they managed?
Are there combination therapies involving minodronic acid that improve osteoporosis treatment outcomes in Japan?